For patients that require non-standard doses, experience swallowing difficulties or receive medication via enteral feeding tubes, compounding oral liquid dosage forms is common and important pharmacy practice [1].
The challenge in compounding oral liquids is that often there is limited information available on the stability of the preparation [1-3]. To overcome this challenge, Fagron has started to study the stability of more than 100 commonly used active pharmaceutical ingredients (APIs) in SyrSpend® SF and publish the results in peer-reviewed scientific journals.
The API concentration for each study has been selected to allow for easy dosing for children and/or adults, based on an extensive review of commonly prescribed concentrations, scientific literature and (inter)national formularies.
The first results of these studies were published this month in the International Journal of Pharmaceutical Compounding. The article shows that SyrSpend® SF is highly compatible with APIs of different pharmacological classes, including:
- Amiodarone HCl
- Furosemide
- Hydrocortisone hemisuccinate
- Hydrocortisone sodium phosphate
- Nifedipine
- Phenobarbital
- Prednisolone sodium phosphate
- Ranitidine HCl
- Simvastatine
- Spironolactone
An overview of all available formulations with SyrSpend® SF can be found in the free online Compounding Matters formulations database.
[1] Glass BD, Haywood A. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. J Pharm Pharmaceut Sci 2006; 9(3):398-426.
[2] Brion F, Nunn AJ, Rieutord A. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr 2003; 92:486-490.
[3] Conroy S. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr 2003; 92:408-410.